These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36267012)

  • 1. Nivolumab plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastroesophageal junction cancer-regional differences in efficacy.
    Mehta R; Shah MA
    Ann Palliat Med; 2022 Oct; 11(10):3371-3375. PubMed ID: 36267012
    [No Abstract]   [Full Text] [Related]  

  • 2. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
    Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
    Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
    Jiang Y; Li Y; Wang LXW
    Int J Clin Pharm; 2022 Apr; 44(2):499-506. PubMed ID: 35088231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New AMM: Nivolumab as an adjuvant for oesophageal and gastroesophageal junction cancer].
    Chartier J; Coutzac C
    Bull Cancer; 2022 Apr; 109(4):389-390. PubMed ID: 35164916
    [No Abstract]   [Full Text] [Related]  

  • 5. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.
    Chen LT; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Sameshima H; Kang YK; Boku N
    Gastric Cancer; 2020 May; 23(3):510-519. PubMed ID: 31863227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of nivolumab versus clinical practice for advanced gastric or gastroesophageal junction cancer.
    Chau I; Ayers D; Goring S; Cope S; Korytowsky B; Abraham P
    J Comp Eff Res; 2020 Jan; 9(2):103-114. PubMed ID: 31872771
    [No Abstract]   [Full Text] [Related]  

  • 7. Nivolumab in gastric/gastroesophageal junction cancer: real-world data from UK Early Access to Medicines Scheme.
    Soni M; Kiff C; Carroll R; Stein D; Saragoussi D; Nassar A; Maisey N; Tyas D
    Future Oncol; 2021 Aug; 17(24):3163-3174. PubMed ID: 34098737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study.
    Yamaguchi K; Boku N; Muro K; Yoshida K; Baba H; Tanaka S; Akamatsu A; Sano T
    Gastric Cancer; 2022 Jan; 25(1):245-253. PubMed ID: 34581902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
    Catenacci DV; Rosales M; Chung HC; H Yoon H; Shen L; Moehler M; Kang YK
    Future Oncol; 2021 Apr; 17(10):1155-1164. PubMed ID: 33263418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer.
    Chau I; Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Sanchez T; Maglinte GA; Laurie M; Abraham P; Patel D; Shangguan T
    Gastric Cancer; 2020 Jan; 23(1):133-141. PubMed ID: 31549264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta-analysis.
    Gong H; Su Y; Zhao L; Ma L; Zhang L; Hou L; Li T; Niu S; Zhang H; Li C; Jin X; Ge L; Leng G; Liu Y
    J Clin Pharm Ther; 2022 Apr; 47(4):493-506. PubMed ID: 34796971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma.
    Ajani JA; Fairweather J; Pisters PW; Charnsangavej C
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):19-21. PubMed ID: 11200143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
    Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
    Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan.
    Kashiwa M; Matsushita R
    Biol Pharm Bull; 2022; 45(7):895-903. PubMed ID: 35786597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: the Improvement in Progression-Free Survival Is Small.
    Mengato D; Chiumente M; Messori A
    J Gastrointest Cancer; 2023 Mar; 54(1):9-10. PubMed ID: 35040033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in esophagogastric cancer.
    Ilson DH
    Clin Adv Hematol Oncol; 2021 Oct; 19(10):639-647. PubMed ID: 34637430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma.
    Qiu HB
    Thorac Cancer; 2020 Dec; 11(12):3419-3421. PubMed ID: 33043992
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of genetic targets on cancer therapy in esophagogastric cancer.
    Jiang Y
    Adv Exp Med Biol; 2013; 779():55-65. PubMed ID: 23288635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASO Perspectives: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer: Never Stop Questioning.
    Schneider BJ; Chang AC
    Ann Surg Oncol; 2022 May; 29(5):2735-2738. PubMed ID: 35182309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.